Company intelligence / Profile preview

Nanode Therapeutics, Inc.

Barrington, RI, United Statesnanodetherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nanode Therapeutics is a development-stage biotechnology company focused on creating innovative nucleic acid therapies using proprietary nanopiece technology to deliver RNAi and other genetic medicines. The company’s work is anchored in technology licensed from Rhode Island Hospital and Brown University. No clinical results are publicly available as the programs appear to be preclinical or early-stage.[3][4][5]

Therapeutic areas: Other
Modalities: RNA interference (RNAi)mRNA therapeuticsDNA/gene therapy[1][4][5]
Industry: Biotech

Drug pipeline

1 asset

anti-miR-181a

Pre-clinical

Indications: Chondrosarcoma

Partnerships

Technology licensed from Rhode Island Hospital and Brown University[3]

Beyond the preview

Go deeper on Nanode Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanode Therapeutics, Inc..

Explore the full profile